Moreover, TLR3 ligand polyI:C treatment significantly decreases the mortality and liver injury caused by injection of lipopolysaccharide (LPS) in the presence of D-galactosamine (D-GalN) in C57BL/6 mice (14), which has driven us to test the anti-inflammatory role of polyI:C during AP progression. The gene discussed is TLR3; the disease is alkaline phosphatase measurement.